Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported top-line data from a double-blind, international Phase III trial in 580 patients with schizophrenia showing that once-daily 40 and 80 mg doses of a transdermal patch formulation of blonanserin both met the primary endpoint of reducing Positive and Negative Syndrome Scale (PANSS) total score from baseline to week six vs. placebo (p=0.007 and p<0.001, respectively). The company plans to submit an NDA in Japan for the product in 2Q18 or 3Q18...